MX2021008010A - Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). - Google Patents

Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).

Info

Publication number
MX2021008010A
MX2021008010A MX2021008010A MX2021008010A MX2021008010A MX 2021008010 A MX2021008010 A MX 2021008010A MX 2021008010 A MX2021008010 A MX 2021008010A MX 2021008010 A MX2021008010 A MX 2021008010A MX 2021008010 A MX2021008010 A MX 2021008010A
Authority
MX
Mexico
Prior art keywords
methods
nafld
fatty liver
liver diseases
alcoholic fatty
Prior art date
Application number
MX2021008010A
Other languages
English (en)
Inventor
Christos Mantzoros
Glenn D Rosen
Original Assignee
Coherus Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Coherus Biosciences Inc filed Critical Coherus Biosciences Inc
Publication of MX2021008010A publication Critical patent/MX2021008010A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se proporcionan en la presente métodos y tratamientos conjuntos útiles para el tratamiento de enfermedades del hígado graso no alcohólico (NAFLD). En particular, se proporcionan en la presente métodos y tratamientos conjuntos para tratar NAFLD mediante la administración de un tratamiento conjunto que comprende (a) el compuesto de la Fórmula (I), o una sal o un solvato aceptable desde el punto de vista farmacéutico de este, y (b) un inhibidor de SGLT-2, o una sal o un solvato aceptable desde el punto de vista farmacéutico de este, y/o (c) un agonista del receptor de GLP-1, o una sal o un solvato aceptable desde el punto de vista farmacéutico de este, y/o (d) metformina. También se proporcionan composiciones farmacéuticas y combinaciones farmacéuticas que comprenden el compuesto de la Fórmula (I) y un inhibidor de SGLT-2 y/o un agonista del receptor de GLP-1 y/o metformina.
MX2021008010A 2018-12-31 2019-12-27 Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld). MX2021008010A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862786618P 2018-12-31 2018-12-31
US201962827349P 2019-04-01 2019-04-01
PCT/US2019/068710 WO2020142365A1 (en) 2018-12-31 2019-12-27 Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)

Publications (1)

Publication Number Publication Date
MX2021008010A true MX2021008010A (es) 2021-10-13

Family

ID=69188008

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021008010A MX2021008010A (es) 2018-12-31 2019-12-27 Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).

Country Status (8)

Country Link
US (1) US20220143003A1 (es)
EP (1) EP3906022A1 (es)
JP (1) JP2022516509A (es)
AU (1) AU2019419390A1 (es)
CA (1) CA3125341A1 (es)
IL (1) IL284345A (es)
MX (1) MX2021008010A (es)
WO (1) WO2020142365A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016229982B2 (en) 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
MX2019011867A (es) 2017-04-03 2020-01-09 Coherus Biosciences Inc Agonista de ppary para el tratamiento de la paralisis supranuclear progresiva.
EP4045042A1 (en) * 2019-10-15 2022-08-24 Coherus Biosciences, Inc. Compositions and methods to treat non-alcoholic fatty liver diseases (nafld)
WO2022051316A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a sglt-2 inhibitor
WO2022051319A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a dpp-4 inhibitor
WO2022051321A1 (en) * 2020-09-03 2022-03-10 Coherus Biosciences, Inc. Fixed dose combinations of chs-131 and a fxr agonist

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6583157B2 (en) 1998-01-29 2003-06-24 Tularik Inc. Quinolinyl and benzothiazolyl modulators
ATE413386T1 (de) 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulatoren
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
AU6118001A (en) 2000-05-03 2001-11-12 Tularik Inc Combination therapeutic compositions and methods of use
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050215882A1 (en) 2004-03-23 2005-09-29 The Regents Of The University Of Michigan Noninvasive method to determine fat content of tissues using MRI
JP5010918B2 (ja) * 2004-07-21 2012-08-29 キッセイ薬品工業株式会社 肝臓脂肪の異常蓄積に起因する疾患の進展抑制剤
MX2016011063A (es) 2014-02-27 2016-11-30 Nusirt Sciences Inc Composiciones y metodos para la reduccion o prevencion de esteatosis hepatica.
CN104299589B (zh) 2014-10-29 2016-05-25 京东方科技集团股份有限公司 移位寄存器单元电路、移位寄存器、驱动方法及显示装置
KR20160061492A (ko) 2014-11-21 2016-06-01 삼성디스플레이 주식회사 휴대용 먼지 센서 및 이를 이용한 휴대전화
AU2016229982B2 (en) * 2015-03-09 2020-06-18 Intekrin Therapeutics, Inc. Methods for the treatment of nonalcoholic fatty liver disease and/or lipodystrophy
US11350844B2 (en) 2016-11-23 2022-06-07 Mayo Foundation For Medical Education And Research System and method for generating nonalcoholic fatty liver disease activity score (NAS) using magnetic resonance elastography
EP3569250A4 (en) * 2017-01-11 2020-11-04 Kowa Company, Ltd. MEDICINAL PRODUCT FOR THE PREVENTION AND TREATMENT OF NON-ALCOHOLIC HEPATIC STEATOSIS

Also Published As

Publication number Publication date
US20220143003A1 (en) 2022-05-12
IL284345A (en) 2021-08-31
AU2019419390A1 (en) 2021-09-02
EP3906022A1 (en) 2021-11-10
WO2020142365A1 (en) 2020-07-09
CA3125341A1 (en) 2020-07-09
WO2020142365A9 (en) 2020-12-10
JP2022516509A (ja) 2022-02-28

Similar Documents

Publication Publication Date Title
MX2021008010A (es) Composiciones y métodos para tratar las enfermedades del hígado graso no alcohólico (nafld).
BR112022012641A2 (pt) Compostos tricíclicos substituídos
PH12019502245A1 (en) Compounds that inhibit mcl-1 protein
PH12020551425A1 (en) Rimegepant for cgrp related disorders
LU92642I2 (fr) Pomalidomide et ses sels, solvates, hydrates ou stéréoisomères pharmaceutiquement acceptables qui endérivent (Imnovid)
PH12019502288A1 (en) Ask1 inhibitor compounds and uses thereof
MX2019012884A (es) Terapia de combinacion.
MX2021006575A (es) Composiciones y metodos para el tratamiento de trastornos del higado.
BR112015020600A2 (pt) composição farmacêutica, método para o tratamento de e/ou melhorar doenças de gordura no fígado de origem não alcoólica e uso da composição
MX2022003102A (es) Degradadores bifuncionales de brd9 y sus metodos de uso.
PH12021550713A1 (en) Medicament for the treatment of chronic cough
WO2020033838A3 (en) Treatment of egfr-mutant cancer
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
JOP20190050A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2022000390A (es) Derivados macrociclicos espirociclicos como inhibidores de mcl-1.
PH12019500618A1 (en) Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease
PH12020500666A1 (en) Pladienolide compounds and their use
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2021007565A (es) Composiciones y metodos para la terapia contra el cancer.
PH12019500858A1 (en) Combination therapy with a phosphoinositide 3-kinase inhibitor with a zinc binding moiety
MX2022008216A (es) Tratamiento de cancer en combinacion usando un antagonista de pd-1, un antagonista de ilt4 y lenvatinib o sales del mismo.
MX2021009206A (es) Terapias contra el cancer.
ZA202201499B (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy